Compare POLA & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POLA | POAI |
|---|---|---|
| Founded | 1979 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 6.5M |
| IPO Year | 2016 | N/A |
| Metric | POLA | POAI |
|---|---|---|
| Price | $1.98 | $5.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.8K | ★ 42.7K |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,326,000.00 | $1,664,407.00 |
| Revenue This Year | N/A | $486.27 |
| Revenue Next Year | N/A | $65.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 320.71 |
| 52 Week Low | $1.53 | $3.88 |
| 52 Week High | $5.75 | $45.90 |
| Indicator | POLA | POAI |
|---|---|---|
| Relative Strength Index (RSI) | 29.28 | 47.30 |
| Support Level | $2.15 | $3.88 |
| Resistance Level | $2.23 | $6.25 |
| Average True Range (ATR) | 0.14 | 0.76 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 4.35 | 79.01 |
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.